Ahlcon Parenterals (india) Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Ahlcon Parenterals (india) Limited Pharmaceutical Export Portfolio Dataset — 5 Products, $11.7M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Ahlcon Parenterals (india) Limited — Pharmaceutical Exporter Profile (2026) | 5 Products, $11.7M Trade | TransData Nexus

Ahlcon Parenterals (india) Limited

Indian Pharmaceutical Exporter · Respiratory Specialist · $11.7M Total Trade · DGFT Verified

Ahlcon Parenterals (india) Limited is an Indian pharmaceutical exporter with a total trade value of $11.7M across 5 products in 2 therapeutic categories. Based on 267 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Salbutamol ($5.9M), Ipratropium ($3.0M), Budesonide ($2.2M).

Ahlcon Parenterals (india) Limited — Export Portfolio & Destination Treemap

Ahlcon Parenterals (india) Limited pharmaceutical export portfolio — 5 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Ahlcon Parenterals (india) Limited? — Company Overview & Market Position

Ahlcon Parenterals (India) Limited, established on January 20, 1992, is a prominent Indian pharmaceutical company specializing in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company is headquartered in New Delhi, India, with its registered office located at Plot No. 30 & 30/E, 2nd Floor, Shivaji Marg, Najafgarh Road Industrial Area, New Delhi, Delhi 110015.

In 2012, Ahlcon Parenterals was acquired by B. Braun Medical (India) Pvt. Ltd., a subsidiary of the German multinational B. Braun Melsungen AG. This acquisition has enhanced the company's quality practices and expanded its business channels. The company is classified as a public limited company under the Corporate Identification Number (CIN) U24239DL1992PLC047245.

As of the latest available data, Ahlcon Parenterals has an authorized share capital of ₹180,000,000 and a paid-up capital of ₹72,001,500. The company employs a dedicated workforce committed to delivering high-quality pharmaceutical products. For more information, visit their official website at www.ahlconindia.com.

What Does Ahlcon Parenterals (india) Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Salbutamol$5.9M

Product Portfolio — Top 5 by Export Value

Ahlcon Parenterals (india) Limited exports 5 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Salbutamol	Respiratory	$5.9M	137	3.3%	3
2	Ipratropium	Respiratory	$3.0M	63	4.4%	2
3	Budesonide	Respiratory	$2.2M	44	0.6%	4
4	Linezolid	Advanced Antibiotics	$540.1K	12	1.4%	11
5	Norfloxacin	Advanced Antibiotics	$168.2K	11	2.0%	12

Ahlcon Parenterals (india) Limited exports 5 pharmaceutical products across 2 therapeutic categories with a total export value of $11.7M. The top category is Respiratory (94.0% of portfolio), followed by Advanced Antibiotics (6.0%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Ahlcon Parenterals (india) Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Ahlcon Parenterals operates state-of-the-art manufacturing facilities located in Bhiwadi, Rajasthan. These facilities are equipped with advanced technology, including aseptic Blow-Fill-Seal (BFS) technology imported from Europe and the U.S., ensuring the production of Large Volume Parenterals (LVP) and Small Volume Parenterals (SVP) in a sterile environment. The company's manufacturing capacity has been expanded over the years to meet both domestic and international demand. Specific capacity details are not publicly disclosed.

3Key Leadership

The leadership team at Ahlcon Parenterals comprises experienced professionals dedicated to steering the company towards growth and excellence. The Managing Director is Indranil Mukherjee, who has been with the company since August 18, 2017. The Chairman is Andreas Walde, serving as a Non-Executive Director since March 18, 2016. Other key executives include Arun Kumar Gupta, Shiv Charan Lal Gupta, Suninder Singh Arora, Christoph Mueller, and Gabriel Sabate Parayre, who hold various directorial positions within the company.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Ahlcon Parenterals (india) Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Ahlcon Parenterals has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company adheres to stringent regulatory standards, ensuring compliance with Good Manufacturing Practices (GMP) and obtaining necessary approvals for its products. While specific regulatory filings and approvals are not publicly disclosed, the company's commitment to quality is evident through its ISO certifications, including ISO 9001:2015 for Quality Management Systems, ISO 14001 for Environmental Management Systems, and ISO 45001 for Occupational Health and Safety Management Systems.

2Emerging Markets

Ahlcon Parenterals has expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's adherence to international quality standards, including ISO certifications, facilitates its entry into these markets. Additionally, the company's association with the B. Braun Group enhances its credibility and acceptance in these regions.

3Geographic Strategy

Ahlcon Parenterals (india) Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Ahlcon Parenterals' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. However, the company's adherence to international quality standards, including ISO certifications, indicates a commitment to meeting regulatory requirements in the U.S. market.

2WHO & EU GMP

Ahlcon Parenterals' manufacturing facilities comply with Good Manufacturing Practices (GMP) standards, as evidenced by its ISO certifications. While specific WHO prequalification and EU GMP certificates are not publicly disclosed, the company's commitment to quality and sustainability aligns with international standards.

3CDSCO & Indian Regulatory

Ahlcon Parenterals holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and relevant state drug controllers, ensuring compliance with Indian regulatory requirements. The company's adherence to ISO standards further demonstrates its commitment to quality and regulatory compliance.

Ahlcon Parenterals (india) Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Ahlcon Parenterals operates in a competitive landscape, facing competition from both domestic and international pharmaceutical companies. While specific market share data is not publicly available, the company's focus on quality, adherence to international standards, and strategic partnerships, such as its association with the B. Braun Group, position it favorably in the market.

2Key Differentiators

Ahlcon Parenterals' key differentiators include its commitment to a Zero Defect Quality policy, utilization of advanced manufacturing technologies like aseptic Blow-Fill-Seal (BFS) technology, and adherence to international quality standards through ISO certifications. The acquisition by B. Braun Medical (India) Pvt. Ltd. has further enhanced its operational capabilities and market reach.

3Strategic Position

Ahlcon Parenterals maintains a strategic focus on manufacturing finished pharmaceutical formulations, including Large Volume Parenterals (LVP) and Small Volume Parenterals (SVP). The company's future outlook includes expanding its presence in both regulated and emerging markets, leveraging its quality manufacturing capabilities and strategic partnerships to drive growth.

Buyer Due Diligence Brief — Evaluating Ahlcon Parenterals (india) Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Ahlcon Parenterals has a strong track record in manufacturing high-quality pharmaceutical formulations, as evidenced by its ISO certifications and adherence to international quality standards. The company's export volume and consistency are supported by its strategic partnerships, including its association with the B. Braun Group. Reliability indicators include its commitment to a Zero Defect Quality policy and utilization of advanced manufacturing technologies.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Registration: Confirm the company's FDA facility registration status through the FDA's official website.

WHO-GMP Certification: Verify WHO Good Manufacturing Practices certification through the World Health Organization's official website.

EU GMP Certification: Check for EU Good Manufacturing Practices certification through the European Medicines Agency's official website.

Frequently Asked Questions — Ahlcon Parenterals (india) Limited

How many pharmaceutical products does Ahlcon Parenterals (india) Limited export from India?

Ahlcon Parenterals (india) Limited exports 5 pharmaceutical products across 2 therapeutic categories. The top exports are Salbutamol ($5.9M), Ipratropium ($3.0M), Budesonide ($2.2M), Linezolid ($540.1K), Norfloxacin ($168.2K). Total export value is $11.7M.

What is Ahlcon Parenterals (india) Limited's total pharmaceutical export value?

Ahlcon Parenterals (india) Limited's total pharmaceutical export value is $11.7M, based on 267 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Ahlcon Parenterals (india) Limited cover?

Ahlcon Parenterals (india) Limited exports across 2 therapeutic categories. The largest are Respiratory (94.0%, 3 products), Advanced Antibiotics (6.0%, 2 products).

Get Full Ahlcon Parenterals (india) Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.